After reshaping itself as a two-sector company with the spinout of its consumer health division this year, Johnson & Johnson posted ongoing gains across its medtech segments—and said it has a “pretty voracious” appetite for device M&A going forward, while it expects rebounds in surgery volume to continue funneling cash into the coffers for the rest of the year.

What do kidney and pancreas transplants have to do with airplane regulations?

The infectious disease diagnostic company MeMed is taking a big step toward a larger market of point-of-care settings, courtesy of a new FDA green light for its test that distinguishes between viral and bacterial cases.

Almost exactly a year after beginning a recall of some of its implantable defibrillator devices that were found to potentially emit electrical pulses below their programmed strength, Medtronic has sent out an even farther-reaching safety alert for a similar issue.

Signant Health acquired fellow trial data specialist DSG for an undisclosed price as part of its plans to expand service offerings for site-based and decentralized clinical studies.

Pfizer has licensed a preclinical cardiovascular program from Riparian Pharmaceuticals as part of an agreement that will also see the Big Pharma support further discovery efforts by the biotech.

Faron Pharmaceuticals has pointed to the latest snapshot of early-stage data as proof that its tumor-associated macrophage candidate bexmarilimab is ready to enter phase 2 trials this year.

Atrial fibrillation. Parkinson’s. Retina degeneration. Optogenetics, a technique that uses light to alter gene expression and thereby control cell activity, is gaining traction both in research and as a potential therapy. Now, scientists have found another possible use for it: drug discovery, specifically for age-driven disease.

Johnson & Johnson’s Abiomed division has received its second Class I recall designation from the FDA in as many months. The agency’s label is reserved for issues with a heightened risk of injury or death.

Beckman Coulter aims to expand its reach in accessible diagnostic tests for Alzheimer’s disease, to get ahead of potentially high demand as advancements are made in hopefully treating the neurodegenerative condition.